FDA puts injection therapy COYA 302 on fast track for treating ALS
Original source
FDA puts injection therapy COYA 302 on fast track for treating ALS (opens in a new tab)Compass holds only the headline and link for this source, so the summary below is necessarily brief. Please read the original.
The U.S. Food and Drug Administration (FDA) granted injection therapy COYA 302 fast-track status for treating amyotrophic lateral sclerosis (ALS). The report does not provide further details about the therapy or the decision.
Why this matters
This is a regulatory development concerning COYA 302 and people affected by ALS. The available source does not establish whether the therapy is safe, effective, approved, or available for treatment.
Limitations and context
This account is based only on the title and metadata of one news report from ALS News Today; its article text was unavailable. The source provides no study size, trial results, peer-review information, or details about the FDA decision. The report itself is journalism, not primary research.